Information  X 
Enter a valid email address

Hikma Pharm Ord Shs 10P (HIK)

Related News

04-Aug-2022 09:00 AM

TOP NEWS: Hikma first half hit by stiff competition for Generics

Hikma Pharmaceuticals PLC shares suffered on Thursday, as it lowered annual guidance after a poor performance in its Generics business hit half-year profit. For the first half of 2022, the London-based pharmaceutical company said pretax profit
24-May-2022 10:29 AM

IN BRIEF: Hikma Pharmaceuticals Chief Executive Siggi Olafsson resigns

Hikma Pharmaceuticals PLC - London-based pharmaceutical company - Says Siggi Olafsson has resigned as chief executive officer and from the board to ‘pursue other opportunities.’ Adds he will remain available to the company until he resigns
05-May-2022 09:24 AM

TOP NEWS: Hikma shares fall 10% on delay to Jazz Pharmaceuticals drug

Shares in Hikma Pharmaceuticals PLC fell early Thursday, after the drugmaker downgraded guidance for its Generics business due to the delayed launch of a generic of the Xyrem treatment for narcolepsy. Hikma shares were down 9.9% at 1,670.00 pen
29-Apr-2022 05:44 PM

IN BRIEF: Hikma says has not entered license agreement with Opiant

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a co
29-Apr-2022 09:09 AM

Hikma Pharmaceuticals notes ‘slow’ start for Generics business in 2022

Hikma Pharmaceuticals PLC said on Friday that both its Injectables and Branded businesses have performed well at the start of the year but noted its Generics business has experienced some headwinds. The London-based pharmaceutical company expla
21-Apr-2022 02:37 PM

IN BRIEF: Hikma Pharmaceuticals completes Custopharm deal

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-b
20-Apr-2022 09:16 AM

IN BRIEF: Hikma gets preliminary US approval for Custopharm acquisition

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injec
25-Feb-2022 09:40 AM

IN BRIEF: Hikma Pharmaceuticals launches first phase of share buyback

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase
24-Feb-2022 10:31 AM

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout. Shares were trading 7.7% lower at 1,857.54 pen
30-Apr-2021 07:43 AM

Hikma Pharmaceuticals lifts guidance on generics business amid 'good' start to year

Pharmaceuticals group Hikma Pharmaceuticals forecast its generics business to generate revenue toward the top end of guidance following a 'good' start to the new year that was in line with its expectations. Full year generics revenue was now e
25-Feb-2021 08:16 AM

Hikma Pharmaceuticals annual profit rises on injectables sales growth

Pharmaceutical company Hikma Pharmaceuticals reported a rise in profit led by growth in its injectables business. For the year ended 31 December 2020, pre-tax profit rose to $558 million from $491 million last year and revenue to rise 6% to $2.34 bill
05-Nov-2020 08:05 AM

Hikma Pharmaceuticals lifts guidance on generics business on strong YTD performance

Hikma Pharmaceuticals lifted its full-year guidance on revenue for its generics segment following stronger-than-expected performance in the year to date. Revenue for generics was lifted to a range of $720 million to $740 million, from previous guidance r
04-Sep-2020 08:20 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to overweight (from equal weight) and raised its price target to 2800p (from 2350p). Story provided by StockMarketWire.com Broker Forecasts data provided by www
14-Aug-2020 09:20 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2350p (from 2200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.u
07-Aug-2020 07:35 AM

Hikma Pharmaceuticals lifts outlook on injectables amid first-half profit beat

Generic pharmaceuticals company Hikma Pharmaceuticals upgraded its outlook on its injectable business after first-half results came in ahead of its expectations on increased demand for Covid-19-related products. For the six months ended 30 June, pre-tax
30-Jul-2020 08:30 AM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2860p (from 2380p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
07-Jul-2020 11:00 AM

Broker Forecast - Morgan Stanley issues a broker note on Hikma Pharmaceuticals PLC

Morgan Stanley today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to overweight (from equal weight) and raised its price target to 2600p (from 2200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.s
30-Apr-2020 07:45 AM

Hikma Pharmaceuticals maintains guidance amid 'strong' start to year

Hikma Pharmaceuticals maintained its guidance and said it had made a 'strong start' to the year despite the challenging market conditions owing to the Covid-19 crisis. The company reiterating its guidance for global injectables revenue growth
28-Apr-2020 11:30 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2200p (from 1950p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.u
24-Apr-2020 10:40 AM

Broker Forecast - Goldman Sachs issues a broker note on Hikma Pharmaceuticals PLC

Goldman Sachs today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to neutral (from buy) and raised its price target to 2400p (from 2200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagaz
07-Apr-2020 10:30 AM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
03-Apr-2020 09:50 AM

Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC

Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2500p (from 2150p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-Apr-2020 10:20 AM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from hold) and raised its price target to 2380p (from 1990p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk.
31-Mar-2020 09:00 AM

Hikma Pharmaceuticals wins ruling to sell, make generic version of Amarin's heart drug

Generic pharmaceutical company Hikma Pharmaceuticals said a U.S. ruled that patents covering Amarin's heart drug were invalid, paving the way for the company to sell generic versions of the drug. Hikma said it was working closely with the U.S. Food
12-Mar-2020 12:50 PM

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2390p (from 2300p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk.

a d v e r t i s e m e n t